ECM
GSK icon

ETrade Capital Management’s GSK GSK Stock Holding History

ETrade Capital Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$2.25M Sell
47,848
-6,979
-13% -$350K 0.04% 210
2020
Q2 		$2.8M Sell
54,827
-14,293
-21% -$733K 0.06% 171
2020
Q1 		$3.27M Sell
69,120
-5,455
-7% -$291K 0.08% 128
2019
Q4 		$4.38M Buy
74,575
+9,290
+14% +$517K 0.1% 117
2019
Q3 		$3.48M Buy
65,285
+947
+1% +$48.7K 0.09% 140
2019
Q2 		$3.22M Sell
64,338
-12,497
-16% -$627K 0.09% 139
2019
Q1 		$4.01M Sell
76,835
-319
-0.4% -$15.9K 0.12% 102
2018
Q4 		$3.69M Sell
77,154
-20,197
-21% -$995K 0.12% 95
2018
Q3 		$4.89M Buy
97,351
+2,427
+3% +$123K 0.14% 81
2018
Q2 		$4.78M Sell
94,924
-956
-1% -$48.1K 0.15% 75
2018
Q1 		$4.68M Buy
95,880
+5,516
+6% +$257K 0.15% 72
2017
Q4 		$4.01M Sell
90,364
-5,156
-5% -$238K 0.13% 90
2017
Q3 		$4.85M Buy
95,520
+11,195
+13% +$568K 0.17% 61
2017
Q2 		$4.54M Buy
84,325
+8,345
+11% +$445K 0.18% 55
2017
Q1 		$4M Buy
75,980
+1,351
+2% +$68.5K 0.16% 65
2016
Q4 		$3.59M Sell
74,629
-16,043
-18% -$792K 0.16% 70
2016
Q3 		$4.89M Buy
90,672
+17,615
+24% +$966K 0.24% 43
2016
Q2 		$3.96M Buy
73,057
+35,497
+95% +$1.87M 0.21% 52
2016
Q1 		$1.9M Buy
37,560
+12,771
+52% +$636K 0.11% 117
2015
Q4 		$1.25M Buy
24,789
+7,010
+39% +$357K 0.07% 155
2015
Q3 		$855K Buy
17,779
+5,628
+46% +$293K 0.05% 192
2015
Q2 		$633K Buy
12,151
+2,657
+28% +$150K 0.04% 254
2015
Q1 		$548K Buy
9,494
+1,991
+27% +$114K 0.03% 273
2014
Q4 		$401K Buy
7,503
+2,698
+56% +$151K 0.02% 350
2014
Q3 		$276K Buy
+4,805
New +$295K 0.02% 383
2014
Q2 		– Sell
-2,091
Closed -$140K – 548
2014
Q1 		$140K Sell
2,091
-2,103
-50% -$142K 0.01% 383
2013
Q4 		$280K Sell
4,194
-1,448
-26% -$93.9K 0.02% 253
2013
Q3 		$354K Buy
5,642
+529
+10% +$34.1K 0.03% 234
2013
Q2 		$320K Buy
+5,113
New +$325K 0.03% 228

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

ETrade Capital Management's GSK Position: Q3 2020 in Review

ETrade Capital Management reduced its GSK (GSK) stake by 13% in Q3 2020, selling an estimated $350K and leaving 47,848 shares worth $2.25M. The position accounts for 0.04% of the portfolio, ranked #210.

ETrade Capital Management first reported a position in GSK in Q2 2013 and has held it in 29 quarters since. The position peaked at $4.89M in Q3 2018. 827 funds tracked by Wall St. Rank hold GSK as of Q3 2020.

  • ETrade Capital Management held 47,848 shares of GSK worth $2.25M as of Q3 2020.
  • ETrade Capital Management sold 6,979 GSK shares in Q3 2020, an estimated $350K.
  • GSK made up 0.04% of ETrade Capital Management's portfolio in Q3 2020, its #210 holding.
  • ETrade Capital Management first reported a position in GSK in Q2 2013 and has held it in 29 quarters since.
  • ETrade Capital Management's GSK position peaked at $4.89M in Q3 2018.
  • 827 funds tracked by Wall St. Rank held GSK as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.